Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
RSC Adv ; 9(66): 38855-38859, 2019 Nov 25.
Article in English | MEDLINE | ID: mdl-35540238

ABSTRACT

The fast Li conductivity of LiBH4 envisages its use in all-solid-state batteries. Powders are commonly applied. But here, we study the formation of dense micrometer films by melting, spinning and subsequent solidifying. Characterized by electron microscopy, and spectroscopy (EDX/XPS/impedance), a reversible phase transformation is confirmed as well as a maximum conductivity of 103 S cm-1.

2.
Sci Rep ; 6: 37229, 2016 11 16.
Article in English | MEDLINE | ID: mdl-27849037

ABSTRACT

Influenza pandemics require rapid deployment of effective vaccines for control. Adjuvants such as AS03 improve vaccine immunogenicity, but this mechanism is poorly understood. We used high-throughput B cell receptor sequencing of plasma cells produced following AS03-adjuvanted and non-adjuvanted 2009 pandemic H1N1 vaccination, as well as pre-pandemic seasonal influenza vaccination to elucidate the effect of the adjuvant on the humoral immune response. By analyzing mutation levels, it was possible to distinguish sequences from cells that were recently activated from naïve B cells from those that were activated by memory recall. We show that the adjuvant functions through two mechanisms. First, the adjuvant stimulates increased activation of naïve B cells, thus reducing immune interference with previous vaccine responses. Second, the adjuvant is able to increase the adaptability of the recalled cells to give improved specificity to the new vaccine antigen. We thus show how AS03 enhances pH1N1 immune responses, and reduces immune interference.


Subject(s)
Influenza A Virus, H1N1 Subtype/drug effects , Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Vaccination/methods , Adjuvants, Immunologic/administration & dosage , Adult , Antibodies, Viral/blood , Antibodies, Viral/immunology , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Double-Blind Method , Drug Combinations , Humans , Immunization Schedule , Influenza A Virus, H1N1 Subtype/immunology , Influenza Vaccines/immunology , Influenza, Human/blood , Influenza, Human/immunology , Polysorbates/administration & dosage , Squalene/administration & dosage , alpha-Tocopherol/administration & dosage
4.
Praxis (Bern 1994) ; 95(13): 501-4, 2006 Mar 29.
Article in German | MEDLINE | ID: mdl-16602671

ABSTRACT

A four-month-old infant was hospitalized because of RSV bronchiolitis. Two days after presentation he developed rhabdomyolysis, most probably as a result of multiple factors (hyperthermia, hypovolemia/dehydration, hypernatremia, metabolic acidosis), followed by severe complications including acute renal failure, hepatic dysfunction and disseminated intravascular coagulation. Under sufficient fluid supply he recovered completely. In rhabdomyolysis clinical symptoms vary. Seldom, the classical trial of muscle pain, weakness, and dark urine is observed. Severe complications are hypovolemia, electrolyte disorders, a compartment syndrome, disseminated intravascular coagulation and acute renal failure, which causes death in 20% of the patients, although non-traumatic causes seem to have better outcome. The mainly therapeutic option is to correct the hypovolemia with sufficient fluid supply.


Subject(s)
Acute Kidney Injury , Bronchiolitis, Viral , Respiratory Syncytial Virus Infections , Rhabdomyolysis , Acute Kidney Injury/diagnosis , Acute Kidney Injury/etiology , Acute Kidney Injury/therapy , Bronchiolitis, Viral/complications , Bronchiolitis, Viral/diagnosis , Diagnosis, Differential , Disseminated Intravascular Coagulation/etiology , Emergencies , Fluid Therapy , Follow-Up Studies , Humans , Infant , Intensive Care Units, Pediatric , Male , Respiratory Syncytial Virus Infections/complications , Respiratory Syncytial Virus Infections/diagnosis , Rhabdomyolysis/complications , Rhabdomyolysis/diagnosis , Rhabdomyolysis/etiology , Rhabdomyolysis/therapy , Time Factors , Treatment Outcome
7.
Bus Insur ; 18(48): 2, 12, 1984 Nov 26.
Article in English | MEDLINE | ID: mdl-10268502
SELECTION OF CITATIONS
SEARCH DETAIL
...